NasdaqGS - Nasdaq Real Time Price USD

Cabaletta Bio, Inc. (CABA)

10.19 +0.26 (+2.67%)
As of 1:10 PM EDT. Market Open.
Loading Chart for CABA
DELL
  • Previous Close 9.93
  • Open 9.94
  • Bid 10.18 x 100
  • Ask 10.24 x 100
  • Day's Range 9.78 - 10.27
  • 52 Week Range 9.55 - 26.35
  • Volume 340,677
  • Avg. Volume 1,147,247
  • Market Cap (intraday) 492.179M
  • Beta (5Y Monthly) 2.52
  • PE Ratio (TTM) --
  • EPS (TTM) -1.71
  • Earnings Date Aug 8, 2024 - Aug 12, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 33.56

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

www.cabalettabio.com

118

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CABA

Performance Overview: CABA

Trailing total returns as of 5/31/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CABA
55.09%
S&P 500
9.21%

1-Year Return

CABA
3.71%
S&P 500
23.86%

3-Year Return

CABA
10.10%
S&P 500
23.91%

5-Year Return

CABA
13.28%
S&P 500
72.34%

Compare To: CABA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CABA

Valuation Measures

Annual
As of 5/30/2024
  • Market Cap

    479.39M

  • Enterprise Value

    263.71M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.16

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -31.16%

  • Return on Equity (ttm)

    -49.06%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -76.87M

  • Diluted EPS (ttm)

    -1.71

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    223.84M

  • Total Debt/Equity (mrq)

    3.68%

  • Levered Free Cash Flow (ttm)

    -38.9M

Research Analysis: CABA

Company Insights: CABA

Research Reports: CABA

People Also Watch